Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26581778 | 0.83 | HRH3 (0.46) | MEN1KMT2AHRH3ALDH1A1KDM4E | |
| SCHEMBL9917380 | 0.81 | HRH3 (0.50) | MEN1KMT2AHRH3ALDH1A1KDM4E | |
| SCHEMBL8967124 | 0.81 | HRH3 (0.50) | MEN1KMT2AHRH3ALDH1A1KDM4E | |
| SCHEMBL9917280 | 0.79 | MEN1 (0.50) | MEN1KMT2AHRH3ALDH1A1L3MBTL1 | |
| SCHEMBL10556823 | 0.78 | HRH3 (0.49) | MEN1KMT2AHRH3KDM4E | |
| SCHEMBL20970396 | 0.77 | NOS3 (0.33) | HRH3 | |
| SCHEMBL13543156 | 0.76 | MEN1 (0.45) | MEN1KMT2AHRH3ALDH1A1KDM4E | |
| SCHEMBL19557971 | 0.76 | CHKA (0.36) | HRH3KDM4EKCNH2 | |
| SCHEMBL22618480 | 0.76 | HRH3 (0.36) | HRH3 | |
| SCHEMBL23683002 | 0.76 | MEN1 (0.47) | MEN1KMT2AHRH3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | MEN1 1816/4885KMT2A 18/4885HRH3 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.